Better medication support for people with HIV and drug‑resistant tuberculosis in South Africa
Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa
This project compares phone-based (mHealth) and regular clinic-based support to help people with HIV and drug-resistant TB in South Africa stay on new medicines like bedaquiline and dolutegravir.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11414832 on NIH RePORTER |
What this research studies
If you join, researchers will test different ways to support you taking both your TB and HIV medicines, including counseling and mobile-phone tools. They focus on people starting new oral drug-resistant TB treatment with bedaquiline alongside dolutegravir-based HIV therapy. The study uses an adaptive design so the types of support that work better can be used more often as the project continues. The work is done at clinics in South Africa and follows participants over time to see how well treatment works and how well people can keep taking their medicines.
Who could benefit from this research
Good fit: Adults living with HIV who are being treated for drug-resistant TB with bedaquiline and who are starting or on dolutegravir-based ART at participating South African clinics.
Not a fit: People who are not receiving care in the study clinics, are not on the specified TB or HIV regimens, or cannot use mobile phones may not benefit or be eligible.
Why it matters
Potential benefit: If successful, this could make it easier for people with HIV and drug-resistant TB to take their medicines correctly and reduce the chance of treatment failure or new drug resistance.
How similar studies have performed: Previous programs using phone reminders and psychosocial support have improved adherence in some groups, but applying these methods specifically to the new bedaquiline and dolutegravir combination in DR-TB/HIV is relatively new.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: O'donnell, Max — Columbia University Health Sciences
- Study coordinator: O'donnell, Max
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.